Kalaris Therapeutics price target raised to $26 from $20 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on Kalaris Therapeutics (KLRS) to $26 from $20 and keeps an Outperform rating on the shares. TH103 demonstrated a strong early efficacy profile, with a mean 10-letter Best Corrected Visual Acuity improvement, a 129 microm central subfield thickness reduction one month after a single dose, and 31% of patients maintaining benefit for six months without anti-VEGF rescue, suggesting meaningful durability, the analyst tells investors in a research note. The firm views any weakness on intraocular inflammation events as an attractive buying opportunity.